Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16447712 | 0.91 | HCRTR2 (0.67) | HCRTR2HCRTR1 | |
| SCHEMBL16447802 | 0.89 | HCRTR2 (0.66) | HCRTR2HCRTR1 | |
| SCHEMBL16447150 | 0.89 | HCRTR2 (0.66) | HCRTR2HCRTR1 | |
| SCHEMBL16447785 | 0.87 | HCRTR2 (0.63) | HCRTR2HCRTR1 | |
| SCHEMBL16453633 | 0.86 | HCRTR2 (0.65) | HCRTR2HCRTR1 | |
| SCHEMBL19518107 | 0.86 | HCRTR2 (0.62) | HCRTR2HCRTR1 | |
| SCHEMBL16453634 | 0.86 | HCRTR2 (0.65) | HCRTR2HCRTR1 | |
| SCHEMBL17724267 | 0.85 | HCRTR2 (0.64) | HCRTR2HCRTR1 | |
| Hydrochloric Acid SCHEMBL17870567 | 0.85 | HCRTR2 (0.64) | HCRTR2HCRTR1 | |
| SCHEMBL17761314 | 0.85 | HCRTR2 (0.64) | HCRTR2HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3030234-B1 | THIAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2018-09-19 | — | — | EP | disclosed |
| US-9695163-B2 | Thiazole orexin receptor antagonists | MERCK SHARP & DOHME CORP (US) | 2017-07-04 | — | — | US | disclosed |
| US-9695163-B2 | Thiazole orexin receptor antagonists | MERCK SHARP & DOHME CORP (US) | 2017-07-04 | — | — | US | disclosed |
| US-9695163-B2 | Thiazole orexin receptor antagonists | MERCK SHARP & DOHME CORP (US) | 2017-07-04 | — | — | US | disclosed |
| US-20160185768-A1 | THIAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-30 | — | — | US | disclosed |
| US-20160185768-A1 | THIAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-30 | — | — | US | disclosed |
| US-20160185768-A1 | THIAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-30 | — | — | US | disclosed |
| WO-2015018027-A1 | THIAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185768-A1 | THIAZOLE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | HCRTR2 1/4885HCRTR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.